The Priority Review

Clinical trials Brief

Teva registers Phase 2b and Phase 3 trials of TEV-53408 in non-segmental vitiligo

The study plans to enroll 1020 participants and start November 16, 2026. TEV-53408 will be compared with placebo to see if it helps bring color back to the skin.

Primary source

ClinicalTrials.gov registry record, November 5, 2026

Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo

Read the source: Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation